INTRODUCTION
Viral vectors are important agents to deliver transgenes into cultured cells, animal models of disease, and humans for gene therapy. Production of these viruses requires a host cell where viral replication and packaging can occur. Although unnecessary for viral synthesis, the transgene is often expressed concomitantly in the packaging cell. Expression of a transgene that is cytotoxic or detrimental to viral production, however, results in a reduction in viral titer, necessitating more starting material to produce useable viral stocks. This also increases the probability of amplifying a virus with unwanted DNA rearrangements in the transgene. Well-known examples of "problematic" transgenes include the pro-apoptotic procaspase 8, Bax and Fas ligand (1, 2) , whose overexpression lowers viral titer by inducing apoptosis in the host cell. Several methodologies have been developed to improve the titer of viruses containing such transgenes, including: (i) inducible systems where the inducing agent is not present during viral synthesis. An example is the GAL4/ VP16-transactivated synthetic promoter, which was used previously in an adenovirus expressing the bax gene (1); (ii) tissue-specific promoters that are not active in the packaging cell. An example is the myelin basic protein promoter previously used to target glioma cells (3); (iii) inhibitors of transgene enzymatic activity. For example, AE25 and 293 cells overexpressing CrmA have been used to improve the titer of adenovirus expressing pro-apoptotic genes (2); (iv) Cre-mediated recombination to activate a transgene after packaging (4); and (v) suppression of transgene expression during packaging using antisense oligonucleotides (5) . Each of these methods has drawbacks. The use of tissue-specific promoters and enzyme inhibitors is restricted to a subset of cell types and transgenes, respectively. Inducible promoters require the subsequent addition to the cells of an inducing agent, which itself may produce undesirable effects. The recombination system requires co-infection of the target cell with a virus expressing Cre recombinase. Antisense oligonucleotides must be resynthesized and retested for each new transgene. We wanted to develop a new method that could be used to package diverse transgenes (both problematic and nonproblematic genes) without the subsequent application of additional reagents.
MATERIALS AND METHODS

Cell Culturing
Neonatal rat cardiac fibroblasts (NRCF) were isolated from the hearts of 1-2-day-old Sprague-Dawley rats as described previously (6 pTRE/SV40-C8 and pTRE/SV40-Tac. Full-length murine procaspase 8 (C8) cDNA was excised from IMAGE clone #3964119 (GenBank Accession #BC006737; Invitrogen) by EcoRINotI digestion and ligated into the EcoRI-NotI sites of pTRE/SV40 to produce pTRE/SV40-C8. A plasmid containing the human Tac antigen cDNA (α subunit of IL-2 receptor or CD25) was purchased from ATCC (Cat. # 39890) (7). The plasmid was partially digested with XbaI, blunted by treatment with T4 DNA polymerase, and then completely digested with XbaI. The resulting XbaI-XbaI(blunt) fragment was subcloned into the NheI-EcoRV sites of pTRE/SV40. A clone was selected with the Tac cDNA in the sense orientation (called pTRE/SV40-Tac).
pTRE MIN /SV40-Luciferase, pTRE/ SV40-Luciferase, and pCMVLuciferase. A BglII-XbaI fragment encoding the luciferase cDNA was excised from the plasmid pGL3-Basic (Promega), and was ligated into the BamHI-NheI sites of pTRE MIN /SV40 and pTRE/SV40 to make the plasmids pTRE M I N /SV40-Luciferase and pTRE/SV40-Luciferase, respectively. To make pCMV-Luciferase a BglIIHindIII fragment encoding the CMV promoter/enhancer was excised from pcDNA3 (Invitrogen), and was ligated into the BglII-HindIII sites of pGL3-Basic. This intermediary plasmid was termed pGL3-CMV. The entire coding cassette was excised from pGL3-CMV with BglII-BamHI(blunted) and was inserted into the BamHI-EcoRV sites of pENTR1A to form pCMV-Luciferase.
ptTs.
A ClaI(blunted)-EcoRI fragment encoding the tTS repressor from the plasmid pTet-tTs (Clontech) was inserted into the XbaI(blunted)-EcoRI sites of pcDNA3 (1). Since it was not required for transient transfections, the neomycin resistance gene was removed from the plasmid by digesting with BstBI, blunting with T4 DNA polymerase, digesting with SmaI, and then resealing with T4 DNA ligase. The resulting plasmid was called ptTs.
Additional Vectors
The expression vector, pcDNA3, was used as a negative control in plasmid transfection experiments. The plasmid pDJM2, expressing β-galactosidase under control of the murine phosphoglycerate kinase (pgk) promoter, was provided by Michael McBurney (University of Ottawa, Ontario, Canada). The vector pSVneo was used to select for stable transfectants and was provided by Paul Berg (Stanford School of Medicine, CA, USA).
Transfection
Cultured cells were transfected with FuGENE 6 Transfection Reagent according to manufacturer's instructions (Roche, Indianapolis, IN, USA). The plasmid to FuGENE ratio (μg: μL) was always 1:2. For HeLa cells, plasmid:FuGENE complexes were dripped directly onto the cells as noted by the manufacturer. For 293A cells, the plasmid:FuGENE complexes were diluted into complete media prior to addition to minimize detachment of the cells from the plate.
Electroporation
For cells that proved difficult to transfect chemically, electro- promoter/enhancer. 293A cells were transiently cotransfected with pTRE/SV40-Luciferase (0.25 μg/well), pDJM2 (0.25 μg/well), and either ptTS or empty plasmid (pcDNA3) (2 μg/well). Twenty four h post-transfection, cells were treated with doxycycline (+Dox, 5 μg/mL with 0.1% DMSO solvent, black bars) or with solvent only (+DMSO, 0.1%, gray bars) for an additional 24 h. Cell lysates were prepared and assayed. Luciferase activities were normalized to that of β-galactosidase and plotted relative to the (ptTS + DMSO) value, which was arbitrarily set as 1. Plotted are means ± SEM (n = 3). **, P < 0.0001; NS, not significant (P = 0.330) compared with corresponding +DMSO value. (B) Comparison of the promoter activities of TRE MIN / SV40 and TRE/SV40 in 293A cells with and without repression. Cells were cotransfected with the indicated luciferase plasmid (0.25 μg/well), pDJM2 (0.25 μg/well), and either ptTS (black bars) or empty vector (pcDNA3, gray bars) (2 μg/well). Cell lysates were prepared 48 h post-transfection and assayed for enzyme activity. Luciferase activity was normalized to that of β-galactosidase to control for differences in transfection efficiency. Plotted are means ± SEM (n = 3) with each mean written above its corresponding bar. (C) Comparison of the promoter activities of TRE MIN /SV40 (white bars), TRE/SV40 (gray bars), and CMV (black bars) in four cultured cell types. Cells were cotransfected with equal masses of the indicated luciferase plasmid and pDJM2, using either FuGENE 6 (HeLa and 293A, 2 μg total plasmid per well) or electroporation (NRCF and Jurkat I9.2, 10 μg total plasmid per cuvette). Cells were assayed 48 h post-transfection. Luciferase activity was normalized to that of β-galactosidase and plotted relative to the pTRE MIN /SV40-Luciferase value, which was arbitrarily set as 1 for each cell type. Plotted are means ± SEM (n = 3). 
were collected and suspended in 400 μL RPMI 1640 containing HEPES buffer. The cells were mixed with plasmid as indicated above and then electroporated (exponential decay, 280 V, 1000 μF). Prewarmed RPMI 1640 with 10% FBS was added and the cells cultured in dishes for 48 h.
Viral Packaging
A plasmid containing the recombinant adenoviral genome was formed by an in vitro recombination between the pENTR1A-derived entry plasmid (i.e., pTRE/SV40-C8 or pTRE/SV40-Tac) and the promoterless destination plasmid pAd/PL-DEST, using Gateway LR Clonase Enzyme Mix according to manufacturer's instructions (Invitrogen). Recombined vector was linearized by PacI digestion and then transfected into 293A cells using FuGENE 6. Cells were fed fresh media every 3 days until cytopathic. Virus was collected by freeze-thaw and titered on 293A cells as plaque forming units (PFU).
Reporter Assays
Cell lysates were assayed for β-galactosidase and luciferase activity essentially as described by Guo et al. (8) . Lysates from untransfected cells were also assayed, and the values subtracted as background. The β-galactosidase activity was calculated as milliunits per microliter of cell lysate, where one milliunit hydrolyzed 1 nmol 2-nitrophenyl β-D-galactopyranoside per minute at 37°C. Luciferase activity was calculated as relative light units per microliter of cell lysate and was normalized to β-galactosidase activity.
RNA Isolation and Northern Blotting for Procaspase 8 (C8) mRNA
RNA was isolated from cells using a RNeasy kit (Qiagen, Valencia, CA, USA) and digested with RNasefree DNase I. Ten μg of total RNA was electrophoresed on a 1% (w/v) agarose gel with formaldehyde and transferred to nylon membrane. Prior to transfer, the gel was stained with SYBR Gold (Invitrogen) and rRNA visualized by blue-light transillumination (Spectroline BlueGlo LED Transilluminator, Spectronics Corp., Westbury, NY, USA). The membrane was fixed, prehybridized, hybridized overnight, and then washed as described previously (9) . Probe template was the 712 bp BglII fragment of IMAGE clone #3964119, which was 32 P-labeled using the Megaprime DNA labeling system (GE Healthcare, Piscataway, NJ, USA). Membranes were exposed to a storage phosphor screen and visualized on the Storm 860 fluorescent scanner (Molecular Dynamics, GE Healthcare).
Generation of the 293A Subclone, tTS-neo8
The plasmids pSVneo and pTettTS were linearized by digestion with EcoRI and HindIII, respectively. Linearized plasmids were cotransfected into 293A cells at a mass ratio of 1:10 (pSVneo: pTet-tTS) using FuGENE 6. Geneticin (Gibco, Invitrogen, 500 μg/ mL) was added to the media at 3 days post-transfection and during all subsequent incubations. After ∼2 weeks, 12 colonies were selected and expanded. The clones were screened by Northern blotting using the tTS cDNA as probe template. The clone with the highest tTS mRNA expression (i.e., tTS-neo8) was selected for further studies.
RESULTS AND DISCUSSION
We developed a new strategy to allow viruses containing "problematic" transgenes to be efficiently packaged. Twenty-four h later the cells were transfected with linearized adenoviral plasmid containing either TRE/SV40-Tac (Tac bars) or TRE/SV40-C8 (C8 bars). Virus was collected and titered as described in Materials and Methods. Plotted are the means ± SEM (n = 3) of the total recovered viral titers in plaque forming units (PFU). NS, not statistically significant from corresponding pcDNA3 value; **, statistically different at P < 0.01. (B) Secondary reamplification using prepackaged virus. One million 293A or tTSneo8 cells were plated per well of a 6-well dish. Twenty-four hours later the cells were infected with ∼1 PFU/cell of the indicated TRE/SV40 adenovirus, which had been packaged using ptTS repression in (A). Upon complete cytopathicity, virus was collected and titered. Plotted are the means ± SEM (n = 6) of viral titers. NS, not statistically significant from corresponding 293A value (P = 0.278); **, statistically different at P < 0.0001. Geneticin was absent from the media of the tTS-neo8 cells both during and after viral infection. (C) Packaged virus maintains a transcriptionally active transgene. NRCF were grown to confluence and transduced with TRE/ SV40-C8 adenovirus, which had been amplified a total of three times using tTS repression, at a multiplicity of infection (MOI) of 50 PFU/cell. Thirty-six h later fibroblasts were harvested and RNA isolated. Ten μg total RNA was subjected to Northern blotting as described in Materials and Methods.
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Short Technical Reports
The system had two components: (i) a multiple cloning sequence (MCS) within the E1 region of the adenoviral genome that was under control of a modified tetracycline-responsive element (TRE) promoter/SV40 enhancer; and (ii) a TRE suppressor (tTS) that was provided in trans. During packaging of recombinant adenovirus, expression of tTS inhibits transcription of the MCS-encoded transgene ( Figure  1A ). Viral particles are packaged and collected as usual. Since tTS is not encoded on the adenoviral genome, it is absent when the resulting virus is used to transduce a target cell. Without the suppressor, the downstream SV40 enhancer stimulates transcription from the TRE and produces strong synthesis of the transgene in the target cell without the need of additional factors ( Figure 1B) .
Prior to packaging a "problematic" transgene in adenovirus, we initially assessed the system using luciferase reporter plasmids. Expression of tTS in transfected 293A cells reduced luciferase activity from the pTRE/SV40-Luciferase reporter by 25-fold ( Figure  2A , gray bars). Doxycycline is known to bind tTS and prevent it from engaging the TRE. Although doxycycline will not be used when packaging virus, its ability to derepress was useful in early proofof-principle experiments. Addition of doxycycline produced a large increase in luciferase activity that was dependent on the presence of tTS (Figure 2A , black bars). Therefore, tTS was able to strongly repress transgene transcription from the hybrid TRE/SV40 promoter/ enhancer. Although strong repression occurs in this system, some residual expression of the transgene with tTS was noted (Figure 2A , ptTS, gray bar). Albeit low, this residual expression could produce problems for highly toxic transgenes. A modified TRE with lower basal activity was also available commercially from Clontech as pTRETight (called pTRE MIN here). When tested in our hybrid system, the relative level of repression by tTS in 293A cells was comparable between the TRE MIN / SV40 and TRE/SV40 promoter/ enhancers, but the absolute level of luciferase expression was approximately 10-fold lower with TRE MIN /SV40 ( Figure 2B ). The availability of both promoter/enhancers should broaden the usefulness of the system to a wider array of "problematic" transgenes.
Promoter activities vary across cell types. In order to ascertain the strength of these new hybrid promoter/ enhancers, the activities of TRE MIN / SV40 and TRE/SV40 were compared with the activity of the widely used CMV promoter/enhancer in four different cultured cell types ( Figure 2C ). Luciferase activity with TRE MIN /SV40 was consistently the lowest, ranging from ∼1/4 that of TRE/SV40 in HeLa cells to ∼1/20 in NRCF. Luciferase levels with TRE/SV40 were ∼1/10 that of CMV in HeLa and 293A and similar to that of CMV in NRCF and Jurkat I9.2 cells. Therefore, although variations exist across cell types, the activity of the TRE/SV40 promoter/ enhancer can be comparable to that of CMV, which is considered one of the strongest promoters in general use.
In order to demonstrate the usefulness of the tTS/TRE/SV40 system to produce virus, murine procaspase 8 (C8) was packaged. It has been shown previously that C8 packages poorly in adenovirus, presumably because its overexpression induces apoptosis in the packaging cell line (2) . Expression of tTS during initial packaging of TRE/ SV40-C8 (i.e., by plasmid transfection of 293A cells) increased adenoviral titer by 22-fold ( Figure 3A , C8 bars). As a negative control, Tac antigen (CD25, IL-2Rα), whose expression has never impacted adenoviral titer in our laboratory (data not shown), was also packaged. As expected, the titer of the TRE/SV40-Tac adenovirus was maximal regardless of the expression of tTS ( Figure 3A, Tac bars) . Therefore, the system improved the initial titer of the "problematic" C8 adenovirus, while having no impact on the packaging of the "nonproblematic" Tac gene.
Transfection of ptTS, which was used for initial packaging, becomes cumbersome for subsequent viral reamplification (i.e., by infection with preexisting virus). To simplify viral production, 293A cells were stably transfected to express the tTS protein (subclone tTS-neo8). There was no significant difference in viral titer between these tTS-neo8 and the parental 293A cells when amplifying the negative control TRE/SV40-Tac ( Figure 3B , Tac bars). However, when amplifying TRE/SV40-C8, a 9-fold greater titer was obtained with the tTS-neo8 cells ( Figure 3B, C8 bars) . Therefore, the titer of the reamplified C8 adenovirus was improved, while the titer of the reamplified Tac adenovirus was not altered. The adenoviral titer of C8 reamplified in tTS-neo8 cells was reproducibly higher than that of Tac for unknown reasons ( Figure 3B , black bars). The absence of deletions and rearrangements in packaged adenoviruses was verified by Southern blotting (data not shown). Also the transcriptional competency of adenovirus in transduced NRCF was verified by Northern blotting for C8 ( Figure 3C ) and Western blotting for Tac (data not shown).
We have developed a new strategy to allow viruses containing "difficult" transgenes to be efficiently packaged and amplified. Both the tTS coding sequence and the TRE (or TRE MIN ) were obtained commercially but were modified and used in a novel way that was not the original intent of the manufacturer (10, 11) . Although tTS has been used previously to reduce leakiness of tetracycline-inducible promoters (12) , to our knowledge this is the first instance of tTS being used to increase viral titer from a constitutively active promoter/enhancer.
There are other methods to package "problematic" transgenes in a virus. The strength of our system is that a transgene can be packaged into a high-titer virus requiring no other agent for activity in a target cell. Coinfection with other viruses, treatment with inducing agents, or co-expression of additional regulatory proteins is not required. Such a broadly active promoter/enhancer will be undesirable in certain situations, especially if tissuerestricted expression in vivo is needed. The enhancer and/or minimal promoter could be replaced with sequences that offer tissue-restricted expression, but we have not tested such a modification. The main disadvantage of our system is that a small amount of transcription still occurs in the presence of tTS ( Figure  2, A and B) . This can be minimized by using TRE MIN /SV40, which gives ∼10-fold lower activity than TRE/ SV40 (Figure 2 , B and C), but a low level of leakiness may still be an issue when packaging extremely toxic genes. However, our system complements others that are currently available and gives the end-user another alternative, which may be advantageous when packaging a "problematic" gene under certain circumstances.
